CRISPR Therapeutics AG (CRSP)

54.07 -0.16 (-0.30%) USD  |  NASDAQ  |  Sep 28, 16:00
54.07 0.00 (0.00%) After-Hours: 17:27
More

CRISPR Therapeutics Cash from Operations (Annual) : -345.01M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for CRSP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2014. Start Trial.
Date Value
December 31, 2025 -345.01M
December 31, 2024 -142.77M
December 31, 2023 -260.38M
December 31, 2022 -495.74M
December 31, 2021 538.97M
December 31, 2020 -238.37M
Date Value
December 31, 2019 56.68M
December 31, 2018 -96.24M
December 31, 2017 -70.09M
December 31, 2016 -55.31M
December 31, 2015 59.43M
December 31, 2014 -4.793M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 3.631B
Basilea Pharmaceutica AG 74.76M
Santhera Pharmaceuticals Holding AG -41.86M
BeOne Medicines Ltd. 1.131B
Intellia Therapeutics, Inc. -394.74M